Pharma Catalysts • Endpoint Arena

Mon, Jun 15, 2026

1 updates

SYRE

8:00 AM

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY002 met its primary endpoint with a statistically significant reduction of 10.7 points (p

Trial Results • Phase 2SKYLINE Part A topline results Mon, Jun 15, 2026spyre.com

Tue, May 5, 2026

1 updates

SYRE

8:00 AM

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class Announced over-enrollment and acceleration of topline readout to the third quarter of 2026 of the

Trial Results • Phase 2spyre.com

Mon, Apr 13, 2026

1 updates

SYRE

7:00 AM

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients

SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p

Trial Results • Phase 2spyre.com